{
    "root": "b73e1972-e96d-4463-ad39-f7bed99466e9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "LURASIDONE HYDROCHLORIDE"
    },
    "value": "20250306",
    "ingredients": [
        {
            "name": "LURASIDONE HYDROCHLORIDE",
            "code": "O0P4I5851I"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (20000 WAMW)",
            "code": "KZQ570MOA5"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "lurasidone hydrochloride tablets indicated : treatment adult adolescent patients ( 13 17 years ) schizophrenia [ ( 14.1 ) ] . monotherapy treatment adult pediatric patients ( 10 17 years ) major depressive episode associated bipolar disorder ( bipolar depression ) [ ( 14.2 ) ] . adjunctive treatment lithium valproate adult patients major depressive episode associated bipolar disorder ( bipolar depression ) [ ( 14.2 ) ] .",
    "contraindications": "lurasidone hydrochloride tablets taken food ( least 350 calories ) . food substantially increases absorption lurasidone hydrochloride tablets ( 2.3 , 12.3 ) . indication starting dose recommended dose schizophrenia \u2013 adults ( 2.1 ) 40 mg per day 40 mg 160 mg per day schizophrenia \u2013 adolescents ( 13 17 years ) ( 2.1 ) 40 mg per day 40 mg 80 mg per day bipolar depression \u2013 adults ( 2.2 ) 20 mg per day 20 mg 120 mg per day bipolar depression \u2013 pediatric patients ( 10 17 years ) ( 2.2 ) 20 mg per day 20 mg 80 mg per day moderate severe renal impairment : recommended starting dose 20 mg per day , maximum recommended dose 80 mg per day ( 2.4 , 8.6 ) . moderate severe hepatic impairment : recommended starting dose 20 mg per day . maximum recommended dose 80 mg per day moderate hepatic impairment 40 mg per day severe hepatic impairment ( 2.5 , 8.7 ) . concomitant moderate cyp3a4 inhibitor ( e.g . , diltiazem ) : lurasidone hydrochloride tablets dose reduced half original dose level . recommended starting dose 20 mg per day . maximum recommended dose 80 mg per day ( 2.6 , 7.1 ) . concomitant moderate cyp3a4 inducer : may necessary increase dose lurasidone hydrochloride tablets ( 2.6 , 7.1 ) .",
    "warningsAndPrecautions": "lurasidone hydrochloride tablets 20 mg white off-white , round shaped , biconvex , film-coated tablets debossed \u201c l \u201d one side \u201c 25 \u201d side . bottles 30 ndc 65862-953-30 bottles 90 ndc 65862-953-90 bottles 500 ndc 65862-953-05 lurasidone hydrochloride tablets 40 mg white off-white , round shaped , biconvex , film-coated tablets debossed \u201c l \u201d one side \u201c 26 \u201d side . bottles 30 ndc 65862-954-30 bottles 90 ndc 65862-954-90 bottles 500 ndc 65862-954-05 lurasidone hydrochloride tablets 60 mg white off-white , oblong shaped , biconvex , film-coated tablets debossed \u201c l \u201d one side \u201c 10 \u201d side . bottles 30 ndc 65862-955-30 bottles 90 ndc 65862-955-90 bottles 500 ndc 65862-955-05 lurasidone hydrochloride tablets 80 mg pale green green color , oval shaped , biconvex , film-coated tablets debossed \u201c l \u201d one side \u201c 27 \u201d side . bottles 30 ndc 65862-956-30 bottles 90 ndc 65862-956-90 bottles 500 ndc 65862-956-05 lurasidone hydrochloride tablets 120 mg white off-white , oval shaped , biconvex , film-coated tablets debossed \u201c l \u201d one side \u201c 29 \u201d side . bottles 30 ndc 65862-957-30 bottles 90 ndc 65862-957-90 bottles 500 ndc 65862-957-05 storage store lurasidone hydrochloride tablets 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "known hypersensitivity lurasidone hydrochloride components formulation . angioedema observed lurasidone [ ( 6.1 ) ] . strong cyp3a4 inhibitors ( e.g . , ketoconazole , clarithromycin , ritonavir , voriconazole , mibefradil , etc . ) [ ( 7.1 ) ] . strong cyp3a4 inducers ( e.g . , rifampin , avasimibe , st. john \u2019 wort , phenytoin , carbamazepine , etc . ) [ ( 7.1 ) ] .",
    "indications_original": "Lurasidone hydrochloride tablets\u00a0are indicated for:\n                  \n                     Treatment of adult\u00a0and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies (14.1)].\n                     \n                     Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].\n                     \n                     Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].",
    "contraindications_original": "Lurasidone hydrochloride tablets should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone hydrochloride tablets (2.3, 12.3). Indication Starting Dose Recommended Dose Schizophrenia \u2013 adults ( 2.1 ) 40 mg per day 40 mg to 160 mg per day Schizophrenia \u2013 adolescents (13 to 17 years) ( 2.1 ) 40 mg per day 40 mg to 80 mg per day Bipolar Depression \u2013 adults ( 2.2 ) 20 mg per day 20 mg to 120 mg per day Bipolar Depression \u2013 pediatric patients (10 to 17 years) ( 2.2 ) 20 mg per day 20 mg to 80 mg per day Moderate and Severe Renal Impairment: Recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day ( 2.4 , 8.6 ). Moderate and Severe Hepatic Impairment: Recommended starting dose is 20 mg per day. The maximum recommended dose is 80 mg per day in moderate hepatic impairment and 40 mg per day in severe hepatic impairment ( 2.5 , 8.7 ). Concomitant Use of a Moderate CYP3A4 inhibitor (e.g., diltiazem): Lurasidone hydrochloride tablets dose should be reduced to half of the original dose level. Recommended starting dose is 20 mg per day. Maximum recommended dose is 80 mg per day ( 2.6 , 7.1 ). Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of lurasidone hydrochloride tablets ( 2.6 , 7.1 ).",
    "warningsAndPrecautions_original": "Lurasidone Hydrochloride Tablets 20 mg are white to off-white, round shaped, biconvex, film-coated tablets debossed with \u201cL\u201d on one side and \u201c25\u201d on other side.\n                      \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 30\u00a0\u00a0\u00a0\u00a0 NDC 65862-953-30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 90\u00a0\u00a0\u00a0\u00a0 NDC 65862-953-90\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 500\u00a0\u00a0 NDC 65862-953-05\n                     \n                         Lurasidone Hydrochloride Tablets 40 mg are white to off-white, round shaped, biconvex, film-coated tablets debossed with \u201cL\u201d on one side and \u201c26\u201d on other side.\n                     \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 30\u00a0\u00a0\u00a0\u00a0 NDC 65862-954-30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 90\u00a0\u00a0\u00a0\u00a0 NDC 65862-954-90\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 500\u00a0\u00a0 NDC 65862-954-05\n                     \n                         Lurasidone Hydrochloride Tablets 60 mg are white to off-white, oblong shaped, biconvex, film-coated tablets debossed with \u201cL\u201d on one side and \u201c10\u201d on other side.\n                      \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 30\u00a0\u00a0\u00a0\u00a0 NDC 65862-955-30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 90\u00a0\u00a0\u00a0\u00a0 NDC 65862-955-90\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 500\u00a0\u00a0 NDC 65862-955-05\n                     \n                         Lurasidone Hydrochloride Tablets 80 mg are pale green to green color, oval shaped, biconvex, film-coated tablets debossed with \u201cL\u201d on one side and \u201c27\u201d on other side.\n                      \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 30\u00a0\u00a0\u00a0\u00a0 NDC 65862-956-30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 90\u00a0\u00a0\u00a0\u00a0 NDC 65862-956-90\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 500\u00a0\u00a0 NDC 65862-956-05\n                     \n                         Lurasidone Hydrochloride Tablets 120 mg are white to off-white, oval shaped, biconvex, film-coated tablets debossed with \u201cL\u201d on one side and \u201c29\u201d on other side.\n                      \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 30\u00a0\u00a0\u00a0\u00a0 NDC 65862-957-30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 90\u00a0\u00a0\u00a0\u00a0 NDC 65862-957-90\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Bottles of 500\u00a0\u00a0 NDC 65862-957-05\n                     \n                        \n                            Storage\n                        \n                     \n                      Store lurasidone hydrochloride tablets at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Known hypersensitivity to lurasidone hydrochloride or any components in the formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.1)].\n                     Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions (7.1)].\u00a0\u00a0\n                     \n                     Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John\u2019s wort, phenytoin, carbamazepine, etc.) [see Drug Interactions (7.1)]."
}